drugset / Trial / NCT02211170

Effect of Single Oral Dose BIRB 796 BS on Endotoxin-induced Inflammatory Responses in Healthy Human Subjects

NCT02211170 ↗

Phase 1 Completed 24 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to determine the effect of a single dose BIRB 796 BS on systemic inflammatory responses induced by endotoxin in healthy humans

Timeline

Start
2000-02
Primary completion
2000-04
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BIBR 796 Unknown 50 mg —
Subject BIBR 796 Unknown 600 mg —

Indications

No indication recorded.